Phase 1b Crossover Trial for Narcolepsy-Cataplexy: Ulotaront Fails to Distinguish from Placebo.

Published Date: 21 Sep 2023

Over a 2-week treatment period, acute and sustained treatment with ulotaront had no statistically significant effect on the overall number of cataplexy events and had no effect on other symptom ratings.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot